GlassScriptPhysician profile
Kara S Gooding
NPI 1538155320
$625,051.47
in general payments reported to CMS, 2019-2025
29 companies · $189K in 2025
The $189K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $92K · 2023: $157K · 2024: $163K · 2025: $189K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $319K · Consulting Fee: $97K · Travel and Lodging: $68K · Food and Beverage: $24K · Honoraria: $305 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $319,016.17 |
| Consulting Fee | $96,556.06 |
| Travel and Lodging | $68,213.63 |
| Food and Beverage | $24,109.57 |
| Honoraria | $305.30 |
| Education | $256.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $155,853.90 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Leo Pharma INC. | $118,953.93 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $62,659.91 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Incyte Corporation | $56,400.04 | 2021-2025 | Opzelura, Opzelura |
| Ucb, INC. | $55,200.74 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $38,139.14 | 2023-2025 | Zoryve |
| Amgen INC. | $37,608.98 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $29,819.49 | 2021-2025 | Aklief, Epsolay, Oracea |
| Almirall LLC | $25,554.92 | 2021-2023 | Klisyri |
| Pfizer INC. | $17,921.71 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $8,352.57 | 2022 | |
| Sun Pharmaceutical Industries INC. | $5,759.70 | 2021-2025 | Winlevi, Absorica Ld, Blu-U |
| Epi Health, LLC | $3,578.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,392.26 | 2021-2025 | |
| Abbvie INC. | $1,528.91 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,519.61 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $1,284.03 | 2021-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $949.99 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma As | $730.75 | 2025 | Adbry |
| Kowa Pharmaceuticals America, INC. | $350.00 | 2025 | Zoryve |
| Genzyme Corporation | $222.20 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $76.97 | 2021-2025 | |
| Biofrontera INC. | $67.46 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $46.27 | 2025 | Nexplanon, Vtama |
| Dermira, INC. | $21.98 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Nabriva Therapeutics, Plc | $15.59 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.85 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Gooding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.